NCT00501631View on ClinicalTrials.gov

ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

March 31, 2011

Conditions
Alcohol Dependence
Interventions
DRUG

VIVITROL 380 mg

Administered via IM injection once every 4 weeks.

DRUG

Placebo for VIVITROL 380 mg

Administered via IM injection once every 4 weeks.

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY